Experimental T-Cell therapy takes on advanced cancers

NCT ID NCT07412665

Not yet recruiting Disease control Sponsor: Beijing Geekgene Technology Co., LTD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new cell therapy called GK01 in 10 people with advanced solid tumors that have stopped responding to standard treatments. The therapy uses the patient's own immune cells (T cells) that are trained to attack the tumor. The main goal is to check safety, but researchers will also look for any signs of tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GK01 cell injection (autologous tumor-reactive T cells)
What this could lead to: If successful, this could point toward a new cell-based treatment option for advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is a very early (Phase 1) and small (10 participants) trial focused on safety, not efficacy. It may not show meaningful tumor shrinkage, and cell therapies carry risks like immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Peking University Cancer Hospital

Beijing, China
Peking University Cancer Hospital

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.